Cns Pharmaceuticals Story

<div class='circular--portrait' style='background:#3b5998;color: #F0F8FF;font-size:4em;'>CP</div>
Lets try to recap the odds of Cns Pharmaceuticals to fully recover from the recent decline as its shares went up 24.86%. Cns Pharmaceuticals's current daily volatility is 5.47 percent, with a beta of 0.06 and an alpha of -0.58 over DOW. While many traders are getting carried away by overanalyzing favorable retirement market, it is reasonable to recap Cns Pharmaceuticals. We will evaluate if Cns Pharmaceuticals shares are reasonably priced going into September.
Published over a month ago
View all stories for Cns Pharmaceuticals | View All Stories
Should you keep an eye on Cns Pharmaceuticals (NASDAQ:CNSP) management before September?
Cns Pharmaceuticals currently holds roughly 2.63 M in cash with (7.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. One of the ways to look at asset utilization of Cns Pharmaceuticals is to check how much profit was generated for every dollar of assets it reports. Cns Pharmaceuticals shows a negative utilization of assets of -170.24 percent, losing $1.7 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cns Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.

How important is Cns Pharmaceuticals's Liquidity

Cns Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Cns Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cns Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cns Pharmaceuticals's total debt and its cash.

How Cns Pharmaceuticals utilizes its cash?

To perform a cash flow analysis of Cns Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cns Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Cns Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Cns Pharmaceuticals Net Cash Flow from Operations is very stable at the moment as compared to the past year. Cns Pharmaceuticals reported last year Net Cash Flow from Operations of (3.55 Million)

Going after Cns Pharmaceuticals Financials

Cns Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.043, which signifies that the company had -0.043% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Cns Pharmaceuticals exposes twenty-seven different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Cns Pharmaceuticals risk adjusted performance of (0.17), and Mean Deviation of 3.14 to double-check the risk estimate we provide.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Over 3 percent roll up for Cns Pharmaceuticals. What does it mean for insiders?

Cns Pharmaceuticals recent standard deviation upswings over 4.41. Cns Pharmaceuticals exhibits very low volatility with skewness of 0.17 and kurtosis of 1.11. However, we advise investors to further study Cns Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Conclusion on Cns Pharmaceuticals

Although some other entities in the biotechnology industry are either recovering or due for a correction, Cns Pharmaceuticals may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither take over new shares of Cns Pharmaceuticals nor quit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cns Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Cns Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com